Lalonde RG - Search Results

1

Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons.

Boulassel MR, Morales R, Murphy T, Lalonde RG, Klein MB. Boulassel MR, et al. Among authors: lalonde rg. J Med Virol. 2006 Sep;78(9):1158-63. doi: 10.1002/jmv.20676. J Med Virol. 2006. PMID: 16847953 Clinical Trial.

2

The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy.

Klein MB, Lalonde RG, Suissa S. Klein MB, et al. Among authors: lalonde rg. J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):365-72. doi: 10.1097/00126334-200307010-00011. J Acquir Immune Defic Syndr. 2003. PMID: 12843748

3

The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection.

Klein MB, Willemot P, Murphy T, Lalonde RG. Klein MB, et al. Among authors: lalonde rg. AIDS. 2004 Sep 24;18(14):1895-904. doi: 10.1097/00002030-200409240-00005. AIDS. 2004. PMID: 15353975

4

Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.

Smith GH, Boulassel MR, Klien M, Gilmore N, MacLeod J, LeBlanc R, René P, Routy JP, Lalonde RG. Smith GH, et al. Among authors: lalonde rg. HIV Clin Trials. 2005 Mar-Apr;6(2):63-72. doi: 10.1310/HAG3-8YA5-UDQC-36NX. HIV Clin Trials. 2005. PMID: 15983890 Clinical Trial.

5

Tuberculosis screening and active tuberculosis among HIV-infected persons in a Canadian tertiary care centre.

Brassard P, Hottes TS, Lalonde RG, Klein MB. Brassard P, et al. Among authors: lalonde rg. Can J Infect Dis Med Microbiol. 2009 Summer;20(2):51-7. doi: 10.1155/2009/658382. Can J Infect Dis Med Microbiol. 2009. PMID: 20514160 Free PMC article.

6

Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker.

Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Al-Mohri H, et al. Among authors: lalonde rg. J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):463-9. doi: 10.1097/QAI.0b013e318030ff8e. J Acquir Immune Defic Syndr. 2007. PMID: 17211282

7

Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare.

Keller M, Lu Y, Lalonde RG, Klein MB. Keller M, et al. Among authors: lalonde rg. AIDS. 2009 Mar 27;23(6):731-7. doi: 10.1097/QAD.0b013e328326f77f. AIDS. 2009. PMID: 19279446

8

The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.

Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piché A, Hankins CA. Beck EJ, et al. AIDS. 2004 Dec 3;18(18):2411-8. AIDS. 2004. PMID: 15622317

9

Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.

Klein MB, Campeol N, Lalonde RG, Brenner B, Wainberg MA. Klein MB, et al. Among authors: lalonde rg. AIDS. 2003 May 2;17(7):1001-8. doi: 10.1097/01.aids.0000060357.78202.25. AIDS. 2003. PMID: 12700449

10

Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.

Raboud JM, Loutfy MR, Su D, Bayoumi AM, Klein MB, Cooper C, Machouf N, Rourke S, Walmsley S, Rachlis A, Harrigan PR, Smieja M, Tsoukas C, Montaner JS, Hogg RS; CANOC Collaboration. Raboud JM, et al. BMC Infect Dis. 2010 Feb 25;10:40. doi: 10.1186/1471-2334-10-40. BMC Infect Dis. 2010. PMID: 20184766 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

79 results

Search Page